Overexpression of human epidermal growth factor receptor (HER-2) occurs in 20–30% of breast cancers and confers survival and proliferative advantages on the tumour cells making HER-2 an ideal therapeutic target for drugs like Herceptin. Here, ERBB2 is linked to breast cancer.